A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
about
A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.Microenvironmental regulation of therapeutic response in cancerSunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastasesVasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Drug rechallenge and treatment beyond progression--implications for drug resistance.Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary NotePotent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Breast cancer causes and treatment: where are we going wrong?Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model.Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.Roadblocks to translational advances on metastasis research.Metronomics as maintenance treatment in oncology: time for chemo-switch.Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.Targeting metastasis.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomyEnhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo.Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.Preclinical mouse solid tumour models: status quo, challenges and perspectives.Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis
P2860
Q30839218-B7858D31-8EA9-4CF9-BC64-75A4FEF65583Q33654609-0007766C-2B7F-4808-A20B-60CF27CE6FDDQ33726477-6EE5B611-1C55-46A9-9402-18F277A03729Q33770680-89C877F2-FA80-412D-9DF6-8B81E23C9CCFQ33913901-57E740A3-CF9A-407B-9B28-6F5F00BCC73AQ34880943-61EE493E-6BCA-40E2-A9C5-ECBA25C4097FQ35376170-57EBA5B4-6BE3-4367-85A0-CBDA8CEF85BAQ35695381-B54686F5-0885-4A84-9E01-8FE30C429B84Q35967416-50E13FAC-069C-425B-B46E-39EACB68FF9AQ36063937-D2F06648-79DA-4569-B5E7-2E2C4ADA7670Q36618871-F56111EC-197E-4624-8D30-F74AE4EDB52EQ37411781-61AA4C84-DA1C-4EA2-8983-418874A86E7DQ37458763-5617D26A-4416-492E-B833-297E999E6D44Q37533025-D0AAFE99-C0A7-476A-883D-73C46EC3C771Q37593526-5788B758-0063-4145-B816-5704EAF68D47Q37595980-DD4EBC6A-725F-4122-BF81-BA41E870A8B7Q37625837-BCA9602F-89F8-4A8D-8199-CAC27220357BQ37660355-B4A8D15E-23BC-4737-B3CA-C22C2E23E1CFQ37679393-DBB33C49-3B45-411A-A26A-5666E0114BE0Q37707573-BE2EF68E-76F4-41A8-A2E5-4A24ADB24181Q38734446-335DDBA6-4FB1-49C2-BC92-BBD7B99B1248Q38786658-35442891-B7B5-4314-90E6-F7CCB95E11F1Q38889516-DEC99A6B-CD54-4B98-AD3B-E4D80282AD33Q38994266-4FE0A29F-C216-4481-AD80-77EA5C1EA105Q41122321-64711963-870B-4CA9-878C-AA681CAAC42DQ42067472-E1874F54-0FD1-4C10-A378-1BFCA8BE139DQ50096902-A3CFD8F6-34D8-4083-8550-181373886409Q50642716-CA3D1FE7-6CBA-4CC1-98AE-C35315078694Q55144204-39D3512F-6658-4870-BC26-4197B93D0AB9Q58217157-28CD275F-CD36-49D1-B111-0D1D90D291D7
P2860
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@ast
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@en
type
label
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@ast
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@en
prefLabel
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@ast
A model of postsurgical advanc ...... icacy of antiangiogenic drugs.
@en
P2093
P2860
P1433
P1476
A model of postsurgical advanc ...... ficacy of antiangiogenic drugs
@en
P2093
Robert S Kerbel
P2860
P304
P356
10.1158/0008-5472.CAN-12-4183
P407
P50
P577
2013-04-22T00:00:00Z